Consensus Clene Inc.

Stocks

CLNN

US1856342019

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
3.850 ^USD	-3.63%		-8.98%	-34.41%

08-14	Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Clene Inc. Announces Biomarker Analyses to Be Included in NDA Submission Supporting ALS Accelerated Approval	CI

Evolution of the Average Target: Clene Inc.

Evolution of the Target Price: Clene Inc.

Changes in Analyst Recommendations: Clene Inc.

65c3677e505fc1649774786e1.-D-nZH293ddgYeaI8jj3_zCIEA_EhNPVTLtByxUiaXY.vXzSMh_quZ8qFt_ggW28pnXRSk7z_qDgL_o1qFkTHxWPV5EGNdil4wIThQ~6029f377da2d41399b9e6d0d773a25bc

Analysts' recommendations: Clene Inc.

24-09-10	EF Hutton Initiates Clene at Buy With $23 Price Target	MT
23-06-30	Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	MT
23-06-21	HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	MT
23-06-20	EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	MT
23-05-16	Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	MT
23-04-10	Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	MT
23-03-10	Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	MT
23-03-08	EF Hutton Starts Clene at Buy With $13 Price Target	MT
22-10-04	Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	MT
22-10-04	Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	MT
22-10-04	Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	MT
22-08-17	Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	MT
22-08-16	Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	MT
22-07-18	HC Wainwright Initiates Clene at Buy With $16 Price Target	MT
22-05-02	Canaccord Genuity Starts Clene at Buy With $10 Price Target	MT
22-02-15	Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	MT
21-11-03	Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	MT
21-09-28	Clene : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	MT
21-05-20	Clene : Maxim Group Starts Clene at Buy With $18 Price Target	MT
21-05-03	Clene : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	MT
21-03-02	Clene : Benchmark Starts Clene at Buy With $25 Price Target	MT
21-02-03	Clene : Roth Capital Starts Clene at Buy with $24 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CLENE INC.					+706.01%
	WUXI APPTEC CO., LTD.					+18.92%
	ARGENX SE					+9.64%
	INSMED INCORPORATED					+58.02%
	WUXI BIOLOGICS (CAYMAN) INC.					+13.1%
	BIONTECH SE					+16.97%
	GENMAB A/S					+10.47%
	PHARMAESSENTIA CORPORATION					+3.5%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.48%
	EXELIXIS, INC.					-9.2%
	Average					+85.19%
	Weighted average by Cap.					+17.24%